Cargando…
MALT1 Inhibition as a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia by Blocking Notch1-Induced NF-κB Activation
Current treatment of T-cell acute lymphoblastic leukemia (T-ALL) is primarily based on high-intensity combination chemotherapy, which has serious side effects. Therefore, developments of novel targeted therapeutics are urgently needed for treatment of T-ALL. In this study, we found that mucosa-assoc...
Autores principales: | Wang, Rong, Zhang, Huihui, Xu, Jiawen, Zhang, Ninghan, Pan, Ting, Zhong, Xiaomin, Zhang, Huanxin, Yin, Lingling, Yao, Yao, Wu, Qingyun, Li, Zhenyu, Liu, Xuejiao, Xu, Kailin, Niu, Mingshan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538650/ https://www.ncbi.nlm.nih.gov/pubmed/33072583 http://dx.doi.org/10.3389/fonc.2020.558339 |
Ejemplares similares
-
High expression of miR-363 predicts poor prognosis and guides treatment selection in acute myeloid leukemia
por: Zhang, Huihui, et al.
Publicado: (2019) -
High expression of miR-25 predicts favorable chemotherapy outcome in patients with acute myeloid leukemia
por: Niu, Mingshan, et al.
Publicado: (2019) -
MiR-425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy
por: Yang, Chen, et al.
Publicado: (2018) -
Preclinical evaluation of the ROCK1 inhibitor, GSK269962A, in acute myeloid leukemia
por: Pan, Ting, et al.
Publicado: (2022) -
MiR-340 Is a Biomarker for Selecting Treatment Between Chemotherapy and Allogeneic Transplantation in Acute Myeloid Leukemia
por: Niu, Mingshan, et al.
Publicado: (2019)